Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.

The KEYNOTE-052 investigated pembrolizumab in the frontline setting, explains Plimack. Additionally, the PD-L1 biomarker and gene signature that predicted full response had been investigated in this trial.

The search for better biomarkers to help select treatment is still requires further investigation states Plimack.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma